06/12/2019

Anapharm Bioanalytics’ successful FDA Inspection

Barcelona. June 12, 2019

Anapharm Bioanalytics is proud to announce that it has successfully undergone another US FDA inspection at its Barcelona based bioanalytical lab. The inspection, that took place in June 2019, had a focus on a total of 8 studies. This was the second unannounced FDA inspection at our facilities without any observations; no 483 form issued.

The regulatory history of Anapharm, which, besides the GLP and ANVISA certifications, includes 14 studies inspected by FDA and another 12 study specific inspections conducted by European authorities, will certainly enable Anapharm Bioanalytics to strengthen its commercial presence throughout Europe and North America and continue to help its customers achieve their registration goals.

“This is the result of the continuous efforts of Anapharm’s team to ensure day after day the highest scientific and quality standards in the work that we do” stated Anapharm’s Director of Business Development, Robert Fontarnau.

About Anapharm Bioanalytics

30+ years’ experience in LC-MS/Bioanalysis and 15+ years’ experience in LBA assays for antibodies and biomarkers, acknowledges Anapharm Bioanalytics as a world class provider of bioanalytical services to international Sponsors with its strategically located, GLP-certified and GCP-compliant laboratory in Barcelona.

With a successful regulatory history, having undergone 20 successful inspections from health agencies, including FDA (14 studies), GCP inspections from Austria, Italy and Spain (12 studies), as well as GLP certifications by EU authorities and ANVISA (Brazil), Anapharm has become a reliable analytical partner to support its clients at any stage of drug development from preclinical throughout all clinical stages Phase I-IV.

MORE NEWS

23/01/2019 10:19

Anapharm Bioanalytics has been acredited under the Gulf Health Council

Anapharm Bioanalytics is proud to announce that it has been recently added to the List of Bioequivalence Centres Approved by GCC, Gulf Cooperation Council (United Arab Emirates, Bahrain, Kingdom of Saudi Arabia, Sultanate of Oman, Qatar, Kuwait and Republic of Yemen).

READ MORE
09/07/2018 11:01

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certificate.
The renewed certification is valid until 11th June 2020.

READ MORE
02/07/2018 11:53

Anapharm Bioanalytics GLP Certificate Renewal

After the corresponding regulatory inspection Anapharm Bioanalytics has renewed once more its Certificate for Good Laboratory Practice Principles (GLP). The company is under GLP certification since its foundation. The present certificate is valid until June 2020.

READ MORE